Pancreatic Cancer Drug Market Share & Growth | Forecast 2031

Pancreatic Cancer Drug Market Share & Growth | Forecast 2031

Segments - Pancreatic Cancer Drug Market by Type (Abraxane, Afinitor, Erlotinib Hydrochloride, Everolimus, Gemcitabine Hydrochloride, Fluorouracil Injection, 5-FU [Fluorouracil Injection], and Others), Application (Clinics and Hospitals), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vineet
Fact-checked by : Vineet Pandey
https://growthmarketreports.com/Vishal
Editor : Vishal Golekar

Upcoming | Report ID :HC-5103 | 4.6 Rating | 75 Reviews | 222 Pages | Format : PDF Excel PPT

Report Description


Pancreatic Cancer Drug Market Outlook 2031

The global pancreatic cancer drug market size was valued at USD 2.49 Billion in 2022 and is likely to reach USD 9.25 Billion by 2031, expanding at a CAGR of 15.7% during the forecast period, 2023–2031. The increasing occurrence of pancreatic cancer and growing demand for drugs to treat the patients are propelling the market.

A pancreas is a small organ situated in the upper abdomen. Pancreatic cancer drugs refer to the medications required for pancreatic cancer treatment, caused by the growth of cancer cells in the pancreas. Irregular growth of cells leads to the formation of tissue lumps called tumors. These cells affect the normal function of the pancreas such as the producing hormones and digestive juices responsible for regulating blood sugar levels in the body.

Pancreatic Cancer Drug Market Outlook

Pancreatic cancer is a rare type of cancer caused in around 2% of total cancer diagnoses every year in the US. According to an article by The Union for International Cancer Control (UICC), about 56,654 new pancreatic cancer cases were reported in the US in 2020.

The two types of pancreatic cancer drugs are exocrine pancreatic cancer and endocrine pancreatic cancer. Enzymes released by pancreatic cells are released into the small intestine and are known as exocrine pancreatic cells. These enzymes facilitate the digestion of food that moves through the digestive tract in the body.


The report finds that the COVID-19 pandemic moderately affected the overall revenue of the global pancreatic cancer drugs market due to the increasing number of virus-infected cases worldwide.

Moreover, the lack of a timely supply of raw materials compelled manufacturers to delay the production of drugs. The fear of contracting the virus leads several patients to either cancel or delay their treatments,
cancer therapies, and appointments. These factors were expected to affect the sale of pancreatic cancer drugs.

Pancreatic Cancer Drug Market Dynamics

Pancreatic Cancer Drug Market Dynamics

Major Drivers

Rise in the number of pancreatic cancer patients and growing demand for treatment drugs are anticipated to drive the market. Growing geriatric population and increasing number of people suffering from obesity result in the occurrence of pancreatic cancer, which in turn, fuels the market. The need for advanced drugs in healthcare and increasing disposable income are expected to drive the market.

Existing Restraints

Pancreatic cancer drugs break the pancreatic cancer cells from the main tumor. These cells enter the bloodstream, which causes the cancer to spread into the other parts of the body. Thus, making these drug inadequate for managing pancreatic cancer.

Emerging Opportunities

Preference for combination of therapies over monotherapy is one of the ongoing trend in the pancreatic cancer drugs market. Thus, manufacturers are investing in combination therapy to increase the efficiency of the drugs and reduce the mortality rate of pancreatic cancer patients.

Additionally, companies are focusing on novel
nanomedicine treatment, as it has potential in pancreatic adenocarcinoma. The nano-formulation of drugs overcomes biological barriers and enhances drug targeting by accumulating on specified sites.

Scope of Pancreatic Cancer Drug Market Report

The report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Pancreatic Cancer Drug Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2022

Historic Data

2016–2021

Forecast Period

2023–2031

Segmentation

Type (Abraxane, Afinitor, Erlotinib Hydrochloride, Everolimus, Gemcitabine Hydrochloride, Fluorouracil Injection, 5-FU [Fluorouracil Injection], and Others) and Application (Clinics and Hospitals)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast

Key Players Covered in the Report

Lilly; F. Hoffmann-La Roche Ltd; CLOVIS ONCOLOGY; PharmaCyte Biotech Inc.; CELGENE CORPORATION; Amgen Inc.; Merck KGaA; Novartis AG; Pfizer Inc.; and Teva Pharmaceutical Industries Ltd.

Pancreatic Cancer Drug Market Segment Insights

Type Segment Analysis

Based on type, the pancreatic cancer drug market is divided into Abraxane (paclitaxel albumin-stabilized nanoparticle formulation), Afinitor (everolimus), erlotinib hydrochloride, everolimus, gemcitabine hydrochloride, fluorouracil injection, 5-fu (fluorouracil injection), and other.

The fluorouracil injection segment is expected to expand at a significant growth rate during the projection period, as it is used to treat a certain type of cancer in chemotherapy, as it helps in killing cancerous cells. The fluorouracil injection is given intravenously or applied as a topical cream, depending on the cancer type, and is used in combination with other drugs.

Pancreatic Cancer Drug Market Type

Application Segment Analysis

On the basis of application, the pancreatic cancer drug market is segmented into clinics and hospitals. The hospitals segment is expected to register a robust pace during the forecast period due to the presence of well-established hospital infrastructure and skilled staff.

Specialized drugs that target cancer cells are used in a hospital setup. Additionally, increasing number of hospitals across the world is projected to boost the segment.

Regional Outlook

In terms of region, the global pancreatic cancer drug market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period due to the increasing adoption of advanced diagnostic solutions and the presence of key manufacturers in the region.

The growth of the market in the region is attributed to factors such as suitable reimbursement scenarios, easy availability of treatment facilities, and relatively high expenditure on healthcare. Additionally, the region witnesses high patient awareness regarding pancreatic cancer willing to invest in advanced technological support for the treatments.

Pancreatic Cancer Drug Market Region

Segments

The pancreatic cancer drug market has been segmented on the basis of

Type

  • Abraxane
  • Afinitor
  • Erlotinib Hydrochloride
  • Everolimus
  • Gemcitabine Hydrochloride
  • Fluorouracil Injection
  • 5-FU [Fluorouracil Injection]
  • Others

Application

  • Clinics
  • Hospitals

Region

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Lilly
  • F. Hoffmann-La Roche Ltd
  • CLOVIS ONCOLOGY
  • PharmaCyte Biotech Inc.
  • CELGENE CORPORATION
  • Amgen Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

Competitive Landscape

Major players operating in the global pancreatic cancer drug market include Lilly; F. Hoffmann-La Roche Ltd; CLOVIS ONCOLOGY; PharmaCyte Biotech Inc.; CELGENE CORPORATION; Amgen Inc.; Merck KGaA; Novartis AG; Pfizer Inc.; and Teva Pharmaceutical Industries Ltd.

These companies adopt strategies such as certifications, partnerships, collaboration, mergers, R&D investments, and product launches to boost their market share. For instance,

  • On April 13, 2022, PharmaCyte Biotech Inc., a biotech company developed cellular therapies for cancer and diabetes by using its advanced live-cell encapsulation technology Cell-in-a-Box. The company announced to accelerate its preparations to start its Phase 2b clinical trial in locally advanced inoperable pancreatic (LAPC) using CypCaps, which is their clinical trial product.

  • On July 27, 2021, Novartis AG announced that US Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for NIS793 in pancreatic cancer. NIS793 is a potential antibody for Transforming Growth Factor Beta.

Pancreatic Cancer Drug Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pancreatic Cancer Drug Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Pancreatic Cancer Drug Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Pancreatic Cancer Drug Market - Supply Chain
  4.5. Global Pancreatic Cancer Drug Market Forecast
     4.5.1. Pancreatic Cancer Drug Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Pancreatic Cancer Drug Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Pancreatic Cancer Drug Market Absolute $ Opportunity
5. Global Pancreatic Cancer Drug Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Pancreatic Cancer Drug Market Size and Volume Forecast by Types
     5.3.1. Abraxane
     5.3.2. Afinitor
     5.3.3. Erlotinib Hydrochloride
     5.3.4. Everolimus
     5.3.5. Gemcitabine Hydrochloride
     5.3.6. Fluorouracil Injection
     5.3.7. 5-FU [Fluorouracil Injection]
     5.3.8. Others
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Pancreatic Cancer Drug Market Analysis and Forecast by Applications
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Applications
     6.2.2. Y-o-Y Growth Projections by Applications
  6.3. Pancreatic Cancer Drug Market Size and Volume Forecast by Applications
     6.3.1. Clinics
     6.3.2. Hospitals
  6.4. Absolute $ Opportunity Assessment by Applications
  6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Pancreatic Cancer Drug Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. Pancreatic Cancer Drug Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global Pancreatic Cancer Drug Demand Share Forecast, 2019-2026
8. North America Pancreatic Cancer Drug Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America Pancreatic Cancer Drug Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America Pancreatic Cancer Drug Market Size and Volume Forecast by Types
     8.4.1. Abraxane
     8.4.2. Afinitor
     8.4.3. Erlotinib Hydrochloride
     8.4.4. Everolimus
     8.4.5. Gemcitabine Hydrochloride
     8.4.6. Fluorouracil Injection
     8.4.7. 5-FU [Fluorouracil Injection]
     8.4.8. Others
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. North America Pancreatic Cancer Drug Market Size and Volume Forecast by Applications
     8.7.1. Clinics
     8.7.2. Hospitals
  8.8. Basis Point Share (BPS) Analysis by Applications
  8.9. Y-o-Y Growth Projections by Applications
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America Pancreatic Cancer Drug Demand Share Forecast, 2019-2026
9. Latin America Pancreatic Cancer Drug Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America Pancreatic Cancer Drug Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America Pancreatic Cancer Drug Market Size and Volume Forecast by Types
     9.4.1. Abraxane
     9.4.2. Afinitor
     9.4.3. Erlotinib Hydrochloride
     9.4.4. Everolimus
     9.4.5. Gemcitabine Hydrochloride
     9.4.6. Fluorouracil Injection
     9.4.7. 5-FU [Fluorouracil Injection]
     9.4.8. Others
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Latin America Pancreatic Cancer Drug Market Size and Volume Forecast by Applications
     9.7.1. Clinics
     9.7.2. Hospitals
  9.8. Basis Point Share (BPS) Analysis by Applications
  9.9. Y-o-Y Growth Projections by Applications
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America Pancreatic Cancer Drug Demand Share Forecast, 2019-2026
10. Europe Pancreatic Cancer Drug Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe Pancreatic Cancer Drug Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe Pancreatic Cancer Drug Market Size and Volume Forecast by Types
     10.4.1. Abraxane
     10.4.2. Afinitor
     10.4.3. Erlotinib Hydrochloride
     10.4.4. Everolimus
     10.4.5. Gemcitabine Hydrochloride
     10.4.6. Fluorouracil Injection
     10.4.7. 5-FU [Fluorouracil Injection]
     10.4.8. Others
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Europe Pancreatic Cancer Drug Market Size and Volume Forecast by Applications
     10.7.1. Clinics
     10.7.2. Hospitals
  10.8. Basis Point Share (BPS) Analysis by Applications
  10.9. Y-o-Y Growth Projections by Applications
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe Pancreatic Cancer Drug Demand Share Forecast, 2019-2026
11. Asia Pacific Pancreatic Cancer Drug Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific Pancreatic Cancer Drug Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific Pancreatic Cancer Drug Market Size and Volume Forecast by Types
     11.4.1. Abraxane
     11.4.2. Afinitor
     11.4.3. Erlotinib Hydrochloride
     11.4.4. Everolimus
     11.4.5. Gemcitabine Hydrochloride
     11.4.6. Fluorouracil Injection
     11.4.7. 5-FU [Fluorouracil Injection]
     11.4.8. Others
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Asia Pacific Pancreatic Cancer Drug Market Size and Volume Forecast by Applications
     11.7.1. Clinics
     11.7.2. Hospitals
  11.8. Basis Point Share (BPS) Analysis by Applications
  11.9. Y-o-Y Growth Projections by Applications
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific Pancreatic Cancer Drug Demand Share Forecast, 2019-2026
12. Middle East & Africa Pancreatic Cancer Drug Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa Pancreatic Cancer Drug Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa Pancreatic Cancer Drug Market Size and Volume Forecast by Types
     12.4.1. Abraxane
     12.4.2. Afinitor
     12.4.3. Erlotinib Hydrochloride
     12.4.4. Everolimus
     12.4.5. Gemcitabine Hydrochloride
     12.4.6. Fluorouracil Injection
     12.4.7. 5-FU [Fluorouracil Injection]
     12.4.8. Others
  12.5. Basis Point Share (BPS) Analysis by Types
  12.6. Y-o-Y Growth Projections by Types
  12.7. Middle East & Africa Pancreatic Cancer Drug Market Size and Volume Forecast by Applications
     12.7.1. Clinics
     12.7.2. Hospitals
  12.8. Basis Point Share (BPS) Analysis by Applications
  12.9. Y-o-Y Growth Projections by Applications
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa Pancreatic Cancer Drug Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global Pancreatic Cancer Drug Market: Market Share Analysis
  13.2. Pancreatic Cancer Drug Distributors and Customers
  13.3. Pancreatic Cancer Drug Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     13.4.1. Lilly
     13.4.2. F. Hoffmann-La Roche Ltd
     13.4.3. CLOVIS ONCOLOGY
     13.4.4. PharmaCyte Biotech Inc.
     13.4.5. CELGENE CORPORATION
     13.4.6. Amgen Inc.
     13.4.7. Merck KGaA
     13.4.8. Novartis AG
     13.4.9. Pfizer Inc.
     13.4.10. Teva Pharmaceutical Industries Ltd.

Methodology

Our Clients

The John Holland Group
Deloitte
Siemens Healthcare
Pfizer
Microsoft
Nestle SA
Honda Motor Co. Ltd.
General Electric